RESEARCH ARTICLE

ASSESSMENT OF THE POTENTIAL AMELIORATING EFFECTS OF BM-MSCs OR INSULIN ON THE ALTERED METABOLIC STATUS OF PANCREAS, LIVER AND KIDNEY IN STZ-DIABETIC RATS.

Wafaa M. El-Kholy1, Reda H. Hussein2 and Dlovan Y. Khalil2.
1. Zoology Department, Faculty of Science, Mansoura University, Egypt.
2. Zoology Department, Faculty of Science, Sylmania University, Kurdistan, Iraq.

Abstract

The current study was designed to investigate the probable hypoglycemic, hypolipidemic and hepato-renal protective effects of bone marrow derived mesenchymal stem cells (BM-MSCs) in comparison with insulin treatment in diabetic rats. Animals were classified into 4 groups; control group, diabetic group (D) received a single IP STZ dose (45 mg/kg b.w), D + insulin (0.75 IU/100 gm bw,SC daily for 4 weeks) group and D + BM-MSCs (single IV dose of $10^6$ cell/rat). Herein, both insulin and BM-MSCs administration significantly improved the hyperglycemic status resulting from diabetes induction, as evidenced by lowered blood glucose, HbA1c and AGEs levels, while enhanced serum insulin, C-peptide and HO-1 levels, compared to the diabetic group. Regarding lipid metabolism, the increased levels of lipid fractions (TL, TG, TC and LDL-C) and the reduced HDL-C level in diabetic rats were reverted back to near normal values as a consequence to BM-MSCs treatment; indicating further, its hypolipidemic effect; in addition to enhancing the protein metabolism in diabetic rats. Furthermore, BM-MSCs was found to has hepato-renal protective effects via improving liver functions in diabetic rats; confirmed by decreased serum AST, ALT, ALP and γ-GT activities associated with decreased total bilirubin but increased total protein and albumin levels; and improving kidney status; indicated by the decreased serum levels of creatinine, uric acid and urea; compared to the diabetic group. Current findings clearly point out the health benefits of BM-MSCs; more than insulin; in ameliorating various metabolic disorders and hepato-renal diabetic complications.

Introduction:

Recent times have witnessed large-scale human dramatic progress in diabetes mellitus (DM) patients count; making it a huge problem and a major health concern across the globe, particularly in the Middle East. It accounts for the 5% of all deaths around the world annually (Alsairafet al., 2018). Approximately 400 million patients worldwide suffer from DM and number is rapidly increasing (Lu et al., 2017).

Type 1 DM (T1DM) is a heterogeneous chronic metabolic disorder due to irregularities in glucose metabolism, as a result of insulin dysregulation that characterized by blood glucose levels elevation with carbohydrate, lipid and protein metabolism disturbances.
protein metabolic abnormalities; accompanied with various serious long-term complications (Chen et al., 2017). It is insulin-dependent resulting from insulin-secreting pancreatic β cells autoimmune destruction (Monfrinai et al., 2017 and Subramanian and Hirsh, 2018). The absence of insulin is life-threatening and generally lethal unless treated with daily exogenous insulin injections by SC route; which is crucial for metabolic optimization (Thakkar et al., 2017).

Lifelong exogenous insulin treatment is still the gold standard and the primary treatment of for these diabetic patients to replaces missing hormone in order to alleviate the symptoms, and nor diet neither exercise can prevent or reverse this type (Xv et al., 2017). However, exogenous injected insulin cannot adequately mimic β cell function sometimes resulting in hypoglycemia, ketosis and coma, that leads to mortality and severe diabetic complications development; such as retinopathy, hepatopathy, nephropathy, neuropathy and multiple cardiovascular problems (Roche et al., 2017).

With no current cure, this disease management focusing now on limiting complications via optimizing blood glucose control (Dewar and Heubergerb, 2017). Because in T1DM patients, β cells majority are lost by an autoimmune attack; injection of insulin only focuses in reversing hyperglycemia, not to increase β cells count (Lu et al., 2017). However, blood glucose optimal control alone could not prevent complications; therefore, to overcome diabetes, the best strategy might be through β cell mass replenish; which promote essentiality using an alternative treatment approaches (Mohan and Nandhakumar, 2014). New β cells generation is an important target in T1DM treatment (Amer et al., 2018); thus, stem cells usage development could be the ideal choice for this disease therapy (Thakkar et al., 2017).

Mesenchymal stem cells (MSCs) found nearly in all tissues; with differentiation capability into various different cell types; holding notable promise in repairing of tissues in a cell replacement manner (Qi et al., 2017). In the area of regenerative medicine, researchers have revealed the BM-MSCs reprogramming potency to become functional insulin producing cells (IPCs); hence, normalizing hyperglycemia in streptozotocin (STZ)-induced diabetic rats (Zang et al., 2017). MSC-related research had demonstrated exciting tissue repair and glycemic control therapeutic effects both in vitro and in vivo(Davies et al., 2016). A plenty of evidence illustrated that MSCs can delay T1DM onset and relieve hyperglycemia via improving pancreatic β cell regeneration, differentiating into IPCs, ameliorating insulin resistance, increase insulin production and promoting the conversion of α cells to β (Zang et al., 2017), thus preventing a lot of long-term complications, improving life quality and minimizing immunosuppression-related side effects.

Taken together, T1DM is a potential candidate disease that may benefit from stem cell replacement protocols. Hence, in this article, we discuss BM-MSCs as an alternative cell source for DM treatment by alleviation and suppression of experimentally-induced diabetic complications; owing to its trans-differentiating capacity into IPCs; and to observe their probable hypoglycemic and hypolipidemic capacities.

Materials And Methods:
Chemicals:
STZ was purchased from MP Biomedicals Company. (Bp 50067, Llkrich, France). While, Insulinagyp containing insulin (100 IU/ml) was produced and supplied by Medical Union Pharmaceuticals Company, Egypt.

BM-MSCs preparation:
Isolated BM-MSCs were obtained from 6–8-week-old rats (the femurs and tibias) and suspended in DMEM media (contain streptomycin/penicillin as an antibiotic and 10% fetal bovine serum); in an atmospheric state of 5% carbon dioxide. Then, morphological characterization was carried out using an inverted microscope to confirm the BM-MSCs identity (Haniza et al., 2016).

BM-MSCs flow cytometric characterization:
BM-MSCs flow cytometric analysis was performed to verify retaining of their phenotype following their expanding in the cell culture. CD44+, CD45+ and CD90+ antibodies were placed against their surface markers: 30 min for the CD45+ antibody and for 4 min for the CD44+ and CD90+ antibodies, all at -20 C; before flow cytometry was assessed (Haniza et al., 2016).
Animals:
100-120 g *Rattus rattus* male albino rats were obtained from the National Research Center, Dokki, Giza, Egypt. They housed in plastic cages and were maintained under conventional laboratory conditions throughout the study, maintained at 22°C under 12 h light/12 h darkness photoperiod. Rats were fed standard pellet chow and water *ad libitum*. After acclimatization for one week, rats were divided into 4 groups each of 6 animals. All experimental procedures were approved by the Ethics Committee in the Faculty of Science, Mansoura University, Mansoura, Egypt.

Induction of diabetes:
Overnight fasting rats were injected with a single IP dose of freshly prepared STZ solution (45 mg/kg bw) dissolved in citrate buffer, pH 4.6. Two days after, diabetes was confirmed by examining blood glucose level using ACCU-CHEKGo apparatus (Roche Company, Germany). Rats with fasting blood glucose level over 200 mg/dl are considered as diabetic (Koroglu et al., 2015).

Experimental design
1. **Control group:** Received IP single dose of citrate buffer (pH 4.6).
2. **Diabetic (D) untreated group:** Received IP single dose of STZ (45 mg/kg bw) dissolved in citrate buffer (pH 4.6).
3. **Diabetic insulin-treated group:** Diabetic rats received SC insulin injection dose (0.75 IU/100 g bw) (Abdel-Razek, 2010), once daily for 4 weeks.
4. **Diabetic BM-MSCs-treated group:** Diabetic rats received IV single dose of BM-MSCs (1x10^6 cell/rat) (Hamza et al., 2016).

Samples collection
At the end of the experimentation period (4 weeks), overnight fasted rats were anesthetized using diethyl ether before being dissected and blood samples were immediately withdrawn directly from the heart. Only few droplets of blood samples were placed in clean heparinized tubes for measuring glycosylated hemoglobin. In clean non-heparinized centrifuge tubes, the remaining of blood samples were collected and let to stand for 15 min, after which they were centrifuged at 3000 rpm for 15 min. Blood sera were carefully separated, labeled and kept at -20 °C for subsequent biochemical analysis. On the other hand, pancreas specimens were quickly separated and an appropriate part was weighed and homogenized forming 10% (w/v) homogenate in distilled water, labeled and kept at -80 °C for subsequent flowcytometric analysis.

Biochemical determinations
Fasting serum glucose and serum HDL-C concentration were estimated using SPINREACT diagnostics kit, Spain. Meanwhile, HbA1c, AGEs and HO-1 were estimated by using kits obtained from Teco Diagnostics, USA. Serum insulin was measured by ELISA kit purchased from Boehringer Mannheim, Germany, using Boehringer Analyzer ES 300; while C-peptide measurement occurred by enzyme immunoassay (EIA) kit purchased from Bio Vision, USA. Serum lipids (TL, TG, TC, LDL-C and HDL-C) and total proteins were estimated using kits from Biodiagnostic Company, Egypt; while serum albumin level was estimated using Diamond Company kit, Egypt. Using kits from ELITech Company, France, serum AST, ALT and γ-GT activities were estimated, while serum ALP activity and total bilirubin, creatinine, urea and uric acid contents were detected using kits from SPINREACT diagnostics kit, Spain.

Statistical analysis
Obtained data were statistically evaluated with SPSS 17.5 software. *P* values equal or less than 0.05 were considered the minimal level of significance. All the results were expressed as the mean ± SE for six animals in each group. Percentage of change in the treated groups was calculated.

Results:
Table 1 illustrate that diabetic group showed a significant increase in serum glucose, HbA1c and AGEs while showed a marked decline in insulin, C-peptide and HO-1 levels when compared to normal control one. The results revealed that treatment of diabetic rats with either insulin or BM-MSCs showed significant amelioration in all tested parameters; except insignificant increase in C-peptide in case of insulin treatment; when compared to the diabetic group. While non-significant changes compared to control group were observed except for C-peptide and HO-1
levels in diabetic rats treated with insulin which were still significantly lower than control. There were no remarkable changes between the results of insulin and BM-MSCs treatments of diabetic rats except for C-peptide and HO-1 which showed a marked enhancement with BM-MSCs than insulin treatment.

The data summarized in table 2 showed a significant increase in all lipid profile parameters in diabetic group; except for HDL-C which showed a marked decrease when compared to normal control one. On the other hand, diabetic rats treated with either insulin or BM-MSCs showed a significant decrease in serum TL, TG, TC and LDL-C levels with a marked elevation in HDL-C level when compared to the diabetic group. While serum TG and TC levels in case of insulin treatment still significantly higher when compared to the control group. Diabetic rat’s treatment with BM-MSCs obtained results displayed non-significant variations in the mentioned parameters compared to diabetic rats treated with insulin.

The represented results in table 3 showed that significant decreases of total proteins, albumin and globulins were seen in diabetic group when compared to normal control one. However, diabetic insulin or BM-MSCs treated groups showed significant increases in all tested parameters levels when compared to the diabetic group. Non-significant changes were shown in the above tested parameters in case of diabetic rats treated with BM-MSCs when compared to the control group; in contrast to diabetic rats treated with insulin results which were still significantly lower. No detectable changes were recorded in both serum TP and albumin levels between the two diabetic rats-treated groups; while a marked enhancement was shown in serum globulins level in BM-MSCs treated group comparing to insulin-treated group.

Results of table 4 demonstrated that diabetic rats showed significant increases in kidney function markers when compared to normal control one. Meanwhile, diabetic rats treated with either insulin or BM-MSCs showed significant decreases in all tested parameters when compared to the diabetic group, although values of urea and uric acid levels in insulin treated group were still significantly higher when compared to normal control group. A non-significant change was detected in creatinine level while a significant decrease in urea and uric acid levels in case of BM-MSCs treated group in comparing to insulin treated group.

Results illustrated in table 5 showed that regarding to diabetic group, significant increases were obtained in liver function markers when compared to normal control one. In contrary, both diabetic treated groups showed significant decline in all tested parameters when compared to the diabetic group. However, values of ALT, γ-GT and total bilirubin still significantly higher in comparing to normal control group. The results reveal a non-significant change in AST, ALP, γ-GT and total bilirubin values between both diabetic treated groups, while ALT level in BM-MSCs treated rats was significantly lower compared to insulin treated rats.

Discussion:-
DM is a global health care issue; with various life-threatening complications; resulting from marked uncontrolled hyperglycemia (Chienet et al., 2015), as a consequence of β-cell insufficiency leading to impairment insulin production or function which highlighting the exogenous insulin need (Kalirai et al., 2017). Because of theirselves-renewal ability, stem cell therapy holds great promise for the damaged tissues and organs repair; making them a candidate for use in regenerative medicine as one of the most promising DM therapies (El Barky et al., 2018).

1. Carbohydrate and glycemic control
The results of the present study showed that a single injection of 45 mg/kg bw of STZ to the rats caused a significant increase in fasting blood glucose (FBG) and blood HbA1c levels as well as in serum advanced glycation end products (AGEs) in contrast to significant decrease in serum insulin and C-peptide levels as well as serum heme oxygenase-1 (HO-1) as compared to the control group. Similarly, participants with diabetes presented with significantly higher FBG and HbA1c, and lower insulin and C-peptide when compared with control subjects (Linet et al., 2017 and Amer et al., 2018). These results are, also, in accordance with the findings of Mayyaset al. (2018)and Nia et al. (2018).

In addition to provoking hyperglycemia, Jaen et al. (2017) cleared that in diabetic dogs there was total or near total loss of insulin secretion, as number of cells producing insulin were reduced. The experiment done by Ghosh et al. (2015)suggested DNA alkylation as the major cause for β-cell death induced by STZ resulting in significant insulin decrease and marked elevation in serum glucose level. Such suggestion was in harmony with the study of Adam et al. (2016) who observed that deviations in control of glucose level, due to STZ injection, is sufficient to trigger an
array of maladaptive processes including decreased serum insulin level with huge signs of pancreatic destruction and glucose transporter-4 (GLUT-4) depletion in the pancreas of diabetic rats compared to control group. However, C-peptide is excised from proinsulin to generate biologically active insulin; it is used to assess endogenous insulin secretion, as its decline is indicative for the insulin production decrease and DM progression (Chen et al., 2017).

HbA1c and AGEs elevated levels; in the present study; in STZ-induced diabetic rats are in accordance with the results revealed a significant HbA1c elevated levels with a marked decrease in the total Hb, which may be attributed to the higher blood glucose levels and its impaired utilization; as HbA1c is produced in a non-enzymatic glycation manner when Hb exposed to excess glucose, serving as an average blood glucose levels marker; and the rate of glycation is proportional to the blood glucose concentration (Muruganathan et al., 2017 and Mayyas et al., 2018).

It was clear from Arcaro et al. (2014) and Hamza et al. (2016) data that extended hyperglycemia causes blood and tissue AGEs accumulation in diabetic rats; which may be due to increased ROS production; having a pivotal role in the long-term diabetic complications development. In hyperglycemia, oxidative stress increased production leads to tissues increase of AGEs and their receptors (RAGE) formation and deposition; inducing NFκB activation and IL increased production (Miyata and Dan, 2012). However, there was a significant decrease in the serum HO-lactivity; a rate-limiting enzyme catalyzes heme breakdown yielding cytoprotective products including carbon monoxide, ferritin and bilirubin; in the diabetic group relative to control (Zhang et al., 2017 and Hamza et al., 2016).

On the other hand; in the current study; marked hypoglycemic effects were shown by either insulin or BM-MSCs treatments in STZ-diabetic rats. Also, their administration raised serum insulin and C-peptide levels as well as HO-1 levels, while significantly lowered blood glucose, HbA1c and AGEs levels to reach nearly normal control values in comparison with diabetic rats. The results, herein, are in harmony with the findings devoted that insulin treatment clearly reversed serum glucose and HbA1c to normal levels in STZ-treated mice (Raccah, 2017); in dogs (Jaen et al., 2017) and in diabetic patients (Katz et al., 2018); causing recurrent hypoglycemia. It was known that, insulin lowers the increased blood glucose level by increasing glycolysis and glucose uptake by insulin-sensitive peripheral tissues like muscle, liver and fat cells; inhibits glycogenolysis and gluconeogenesis in the liver; and inhibits lipolysis in adipose tissue (Jaen et al., 2017). Furthermore, insulin injection could directly affects glucose metabolism in STZ-diabetic rats via glucokinase and pyruvate kinase gene expressions up-regulation; the key rate-limiting enzymes mediating glucose oxidation and ATP generation (Janshidi et al., 2018).

There is no doubt that BM-MSCs have therapeutic effects on diabetes; as they are able to stimulate damaged pancreatic β-cells regeneration and becoming an alternative β cell source after induction; making them an ideal choice for DM treatment. Wang et al. (2014) and Sood et al. (2015) proved that BM-MSCs treatment resulted in HbA1c levels and insulin requirement reductions in diabetic rats, and in 9 out of 11 diabetic patients Bhansali et al. (2014). Hypoglycemic therapeutic potential of MSC transplantation may be a direct effect of their intrinsic regenerative capacity and differentiation into IPCs, insulin release in a glucose-dependent manner, improving diabetic symptoms in T1DM animal (less likely) and preserve residual β-cell mass; or an indirect effect of immunomodulators secretion, thus, arresting autoimmune T cells from inducing destruction to the pancreatic β-cell (Monfrini et al., 2017 and Thakkar et al., 2017). This is confirmed, also, by Zang et al. (2017) whereported thatMSCs exert beneficial effects on glycemic control as insulin requirements decreased by 50%; by ameliorating insulin resistance and restoring islet function; through promotion of islet cell regeneration, differentiation into IPCs, protection of endogenous islet cells and promote trans-differentiation of a cells into β cells followed by β cell mass restoration and dramatic hyperglycemia amelioration, in mice with STZ-induced T2DM.

Recently confirming this regard, Amer et al. (2018) revealed that transplanted IPCs differentiated from Ad-MSCs in STZ-diabetic rats; showed marked pancreatic β cell markers expression, apparent islet cells regeneration and proliferation and significant increase in C-peptide with increased insulin secretion in glucose dependent manner. Interestingly, MSCs infusion during the early phase (7 days) could ameliorate pancreatic islets destruction, restore β-cell function, reduce insulin resistance and promote MSCs recruitment to the damaged tissues; whereas late phase infusion (21 days) merely ameliorated insulin resistance (Si et al., 2017). Meanwhile, FBG insulin requirement and HbA1c levels were decreased while C-peptide level was increased, in diabetic rats after BM-MSCs therapy for 3 months (Thakkar et al., 2016), 6 months (Liu et al., 2014) or 12 months (Wang et al., 2015), compared with the diabetic control therapy; due to prevent islet cell loss, elevated insulin secretion from existing β-cells and insulin biosynthesis marked increase, suggesting improvement in the islet β cells number and/or function (Li et al., 2016).
Herein, the insignificant increase of serum C-peptide level in insulin treated group, in contrast to its huge significant increase in BM-MSCs treated group, clearly confirms the importance of BM-MSCs as a therapeutic adjunct for diabetes cure. The most probable explanation for this was that MSCs rapid infusion could improve remnant β cell regeneration and proliferation, leading to an endogenous insulin secretion elevation; minimizing the exogenous insulin injection need.

2. Lipid profile
Insulin deficiency and dysregulated lipid metabolism are major causes of DM (Chen, 2016). For lipid metabolism, STZ diabetic rats in the present work showed a great disturbance in lipid profile as they exhibited significant increase in serum TL, TG and TC in addition to LDL-C levels while a significant decrease in serum HDL-C level was seen compared to the control group. However, progression of dyslipidemia was related to glycemic control (Katzet al., 2018), as increased lipid levels with huge signs of pancreatic destruction were observed in diabetic subjects (Adam et al., 2016). These results are in agreement with those obtained by Antony et al. (2017) and Lin et al. (2017) who reported that, in STZ diabetic rats, the primary quantitative lipoprotein disturbance defects are glycation of apolipoproteins, elevated TG, VLDL-C and LDL-C levels with HDL-C decline, and elevated ability of LDL-C to oxidation. Nonetheless, LDL is more likely to be oxidized and glycated, while HDL undergoes increased catabolism (Cariou et al., 2017).

In fact, lipoidosis considered the primarily pathological change in DM complications, as some experts preferred that there might be more rewarding to approach it as “lipocentric” than “glucocentric”. Dyslipidemia development is associated with insulin resistance; and once hyperglycemia is present, increased hepatic free fatty acid synthesis and influx driven by concomitant glycemic control and insulin sensitivity loss, cause dyslipidemia to deteriorate further (Li et al., 2012).

Both inflammation and insulin signal pathways have key roles in deficiency of insulin and accumulation of fats (Chen, 2016). As a consequence of insulin deficiency; since insulin inhibits lipase hormone; serum fatty acids excess promotes its conversion into hepatic cholesterol and phospholipids, which along with formed hepatic TG excess; may be discharged into the blood in the form of lipoproteins. Unoxidized long-chain fatty acids over accumulation causes a ‘spill over’ of lipids into non-adipose tissues, like heart, muscle, liver as well as pancreatic islets; promoting programmed cell-death (lipoapoptosis) and metabolically relevant cellular dysfunction (lipotoxicity) in these tissues (Krijnen et al., 2009). In addition, according to Titchenellet al. (2017); during DM; insulin fails to suppress hepatic glucose production but promotes lipid synthesis leading to hyperglycemia and hypertriglyceridemia. Deviations in control of glucose level is sufficient to trigger an array of maladaptive processes including changes in the oxidation of free fatty acid (Huynh et al., 2014). In DM, liver exhibits abnormally high levels of triglyceride and cholesterol synthesis, resulting in marked dyslipidemia (Giralt et al., 2018).

On the other hand, in the present study, either insulin or BM-MSCs administration to diabetic rats greatly counteracted lipid profile as compared to diabetic group. T1DM Patients under good glycemic control often have a ‘supernormal’ lipid profile, and subcutaneous insulin administration could increase lipoprotein lipase activity leading to VLDL-C particles turnover (Cariou et al., 2017). These results agree also with those of Jaen et al. (2017) who stated that throughout the 8-year follow-up period, diabetic dogs treated with insulin showed normal serum levels of TL, TG and TC comparing to diabetic group, that reduce the risk for cardiac disease in diabetic subjects. In addition to its antiatherogenic action, HDL-C may also have an antidiabetic function, through its protective role for insulin resistance and DM incidence exacerbation (Tabaraet al., 2017). Moreover, Katz et al. (2018) reported that insulin therapy dampened the increase in TL, TG, TC and LDL-C.

However, Lin et al. (2013) found that WT-MSC transplantations resulted in lipoprotein lipase upregulation and reduced fatty acid synthase mRNA levels in the adipose tissues of high-fat/sucrose diet-fed mice, indicating a marked hypolipidemic ability. Meanwhile, BM-MSCs at 8 weeks of treatment; in high fat diet- and STZ-diabetic mice; prevented excessive lipid accumulation and reversed insulin resistance (Nagaishi et al., 2014). Furthermore, the results of Gao et al. (2014) suggested that MSC could attenuate the diabetic adipocytes abnormal function, via up-regulation of GLUT4 expression and PI3K/AKT insulin signaling pathway associated with an increased MSCs-insulin-like growth factor-1 (IGF-1) secretion.
3. Protein metabolism

Evidence shows that DM metabolism disturbances not applies to glucose and lipid only but protein metabolism as well (Gougeon, 2013). Concerning proteins, the present study demonstrated that serum total proteins, serum albumin and globulins levels were significantly decreased in diabetic rats. These results are comparable with those of other studies illustrating that the marked changes in the level of total proteins reflect disorders in the synthesis and metabolism of proteins (El-Kholy et al., 2011 and Manjusha et al., 2012).

Many reports had suggested a marked muscle and lean tissue strength loss with aging in DM (Gougeon, 2013). It could be observed that the average weight of diabetic rats, serum albumin, globulins and total protein levels decreased significantly after STZ injection, with respect to the control group (Hamza et al., 2016 and Antony et al., 2017). The results also are in accordance with those of Arya et al. (2012) who reported that there were significant decreases in plasma protein, albumin and globulin levels in STZ-induced diabetic rats as a consequence to acute liver damage leading to the decrease of their synthesis in liver.

The reduced use of glucose as a source of energy and oxidative stress, besides liver metabolic abnormalities, could induce an energy depletion; resulting in substantial protein and weight loss (Jamshid et al., 2018). However, the decrease in total proteins as well as albumin and globulin levels in serum of diabetic rats may be attributed to several reasons such as increased gluconeogenesis, decreased amino acid uptake, hepatic damage and disintegration and/or dissociation of polyribosomes from endoplasmic reticulum (Singh and Kakkar, 2013). Furthermore, it seems likely to suggest that insulin lack would decrease amino acids incorporation into proteins and/or may decrease protein synthesis; as insulin deficiency in vivo is associated with enhanced protein breakdown, amino acids levels elevation and negative nitrogen balance in diabetic rats (Ene et al., 2007). According to Hebert and Nair (2010) protein metabolism is markedly altered during insulin deprivation, since there was a net protein loss; because of the great whole-body protein breakdown increase than protein synthesis.

Herein, diabetic rat's treatment with insulin or BM-MSCs cause a significant increase in serum total proteins, albumin and globulins in comparable to diabetic group. Insulin has a critical role in maintaining proteostasis, via regulation of protein degradation and synthesis as well as post-translational modifications at the tissue and the organism level (James et al., 2017). Insulin treatment clearly causes protein and weight gain, perhaps through controlling the elevated serum glucose level (Herman et al., 2017). Thus, we can assume that insulin injection and BM-MSCs administration in our study consequently leads to a marked elevation in serum insulin levels which help in restoration of appropriate protein metabolism balance.

4. Kidney functions

In DM, kidney is an important target organ, as hyperglycemia, activated inflammation and innate immunity are relevant factors in the microvascular diabetic complications development, as they can stimulate free radical's production and renal cells apoptosis induction leading to diabetic nephropathy (DN) (Elmarakby et al., 2012). Our results indicate that, in cases of diabetes induced by STZ injection, a marked increase in the serum urea, uric acid and creatinine levels have been noted.

The results of the present experiment coincide with those in the study conducted by Hamza et al. (2016) and Antony et al., (2017) in which they determined that high glucose levels and ROS leads to serious kidney damage that revealed significant increase in serum uric acid, urea and creatinine, in diabetic group with respect to the control group. According to Feig et al. (2008), a high concentration of uric acid has been associated with T2DM, as insulin resistance causes acidic urine; as uric acid stones tend to form in the low pH urine. One of the reasonable explanation for the DN is that hyperglycemia-induced apoptosis in various renal cell types especially to the glomerular podocyte (epithelial cells attached to the glomerular basement membrane), leading to albuminuria; which are DN critical early events (Dawe et al., 2014 and Jiang et al., 2016). Another explanation is that HO-1 reduction can seriously results in DN; while its induction is protective in many chronic and acute renal insults; as renal HO-1 expression up-regulation could improve both renal and function vascular (Pitlovancvet et al. 2013). These findings supported those of Elmarakby et al. (2012). More recently, Xie et al. (2018) reported that chronic kidney disease (CKD) is characterized by glucose and insulin homeostasis disturbances, increases insulin resistance and; in advanced stages; results in β-cell dysfunction and defective insulin secretion, and this combination led to observation of a higher glucose intolerance prevalence. Although experimental evidence identifies urea as a putative culprit, higher urea level may suppress insulin secretion and increase insulin resistance. In this regard, Thomas et al.
(2015) and Koppe et al. (2016) suggest that insulin secretion defection in CKD advanced stages is mechanistically caused by increased serum urea level.

On the other hand, BM-MSCs contribute to cell turnover and repair in various tissue types, including kidneys. Because nephrons are of mesenchymal origin, MSCs are attractive candidates for renal repair. Diabetic rat's treatment with either insulin or BM-MSCs, herein, resulted in significant reduction in serum urea, uric acid and creatinine levels compared to the diabetic control. In harmony with our findings, the study of Hanza et al. (2016) revealed that BM-MSCs therapy was found to have a positive effect on the kidney functions as it showed significant serum creatinine, urea and uric acid levels reduction; compared to the untreated groups; since treatment recovered the organizational structure of both pancreas and kidney, as demonstrated by the histopathological analysis. The result of systemic administration of MSCs after STZ-induction of DM indicated reversed hyperglycemia associated with pancreatic β-islets regeneration and kidney function improvement (Zhou et al., 2016). Li et al. (2014) found that mice treated with MSCs exhibited reduced proteinuria and BUN and ameliorated renal pathological damage as MSCs migrated to the kidney, compared with glomerulonephritis mice. In consistent with these results, Pitlovanciw et al. (2013) stated that treatment of diabetic rats with MSCs could maintain serum urea and creatinine near the normal levels suggesting their beneficial role in providing protection against DN; either directly or indirectly.

Immunomodulators expression modification was proposed as a possible mechanism for MSCs reno-protective effects. Fang et al. (2012) cleared that MSC implantation significantly reduce renal tissues damage, via oxidative stress and inflammatory response suppression. Similar results were obtained by Wang et al. (2013) who found that administration of BM-MSCs via the left renal artery of diabetic rats prevented albuminuria, creatinine clearance rate, urinary albumin to creatinine ratio development and preserve normal renal histology, suggesting a paracrine mode of action with MSCs exerting their beneficial effects by increasing of the podocyte survival factor BMP-7 expression. In this line, MSC treatment ameliorated DN; through inhibiting MCP-1expression, thus reducing macrophage infiltration and down-regulating TNF-α, IL-1B and IL-6 expressions in diabetic rat's renal tissue (Liet al., 2013). Furthermore, MSC can produce a large number of soluble factors (chemokines, cytokines and growth factors); in response to inflammatory mediators; capable of regulating inflammation and tissue remodeling; suggesting that the transient presence of MSCs within the injured kidneys may provide a paracrine support rather than a direct effect for the healing process and cell damage repair (Jiang et al., 2016 and Sordia et al., 2017).

These results support the suggestions that BM-MSCs may home to injured glomerular endothelium, differentiate into endothelial cells and participate in glomerular microvasculature regeneration (Rookmaaker et al., 2007). However, BM-MSCs contribute to the renal tubular cell regenerating, via its capability in accelerating tubular proliferation, improve renal function and repair renal injury as well as HO-1 expression up-regulation; which has been shown, in animal models, to exert a renal function protective effect (Yener et al., 2008). These findings are in good agreement with our results.

5. Liver functions

There is a particularity of liver diseases during diabetes, including hepatitis C virus infection, cirrhosis, and metabolic steatosis (Petit, 2017). Diabetes is a metabolic disease which leads to significant increase in free radicals prompting liver diseases development via fibrogenesis, inflammatory response and hepatocyte apoptosis induction (Ghosh et al., 2015). Liver histopathological evaluation showed the high blood glucose level deleterious effects in the forms of fatty degeneration and microvascular steatosis (Janshidi et al., 2018).

The data obtained by the present study showed that serum AST, ALT, ALP, γ-GT activities as well as total bilirubin level obviously increased in diabetic rats compared with normal control. These results are compatible with the findings obtained by Ramesh et al. (2012); Sirasanagandaet al. (2013) and Xie et al. (2014) who found these enzymes leakage into the blood stream from the liver cytosol; indicating hepatocytes damage due to increased oxidative stress, liver dysfunction, enzymes biosynthesis disturbance with liver membrane permeability alteration. This is confirmed by Antony et al., (2017) and Muruganathan et al. (2017) who stated that serum AST, ALT and γ-GT activities increased in STZ-diabetic rats in response to marked hepatic abnormalities. Furthermore, severe hepatic damage in the STZ groups was noticed through serum AST, ALT and ALP fluctuating levels; which result from these mitochondrial, cytosolic, and extracellular enzymes leakages to the blood stream (Janshidi et al., 2018).
In accordance with El-Sharkeyet et al. (2007) results, diabetes was found to increase the serum total bilirubin perhaps due to the decreased liver uptake and/or conjugation or increased bilirubin production due to accelerated RBCs hemolysis indicating presence of both hematological and liver problems. The excessive production of free radical in diabetes may be another explanation, since the clearance of serum bilirubin was associated with free radical production (Ocheet et al., 2014). Lastly, plasma bilirubin level elevation may be attributed to periportal necrosis confirming liver damage incidence (Newairyet al., 2009).

On the other hand, different liver diseases may involve different nutritional management, glycemic monitoring, and the use of antidiabetic therapies (Petit, 2017). BM-MSCs therapy can be mediated by enhancing endogenous hepatocyte regenerative processes, which can improve liver function in advanced chronic liver disease (Kumar et al., 2011). The data, herein, showed that diabetic rats treatment with either insulin or BM-MSCs resulted in a significant amelioration in the serum enzyme levels and this improvement demonstrated the protective effect of them on hepatocytes structure and function in diabetic rats.

Insulin-loaded nanoparticles decreased hepatic inflammations via suppressing the necro-inflammatory process in the diabetic liver histopathology, which is in line with the reduction of the liver enzymes activities (ALP, ALT, and AST); as liver degenerative changes marker (Janshidet et al., 2018). Ning et al. (2016) hypothesized that insulin augments and protects the hepatocyte sensitivity to saturated fatty acids-induced lipotoxicity, based on the decline in LDH activity and caspase-3 expression, mechanistically through alleviating ER stress via a PI3K/Akt/p53 involved pathway, contributed to its hepatoprotective role.

Given their unique function in differentiation potential and self-renewal, MSCs might be used to regenerate damaged liver tissue. Recent studies have shown that MSCs-based therapies can improve liver function in a mouse model of hepatic failure (Lee et al., 2018). Similarly, assessment of serum parameters including AST, ALT and total bilirubin, at day 7 exhibited significant reduction, after BM-MSCs in an animal model of CCl4-induced acute hepatic failure; compared with the control group (Fathi-Kazeroomiet al., 2017). Additionally, Ramanathan et al. (2017) found that hepatic pathological changes were significantly restored in d-Galactosamine induced acute liver injury in mice that received WJ-MSCs; showed by the significant decline in AST, ALT, ALP and total bilirubin serum levels; compared to control; indicating hepatoprotective and probable regenerative property.

BM- MSCs was effective in rescuing experimental CCl4-induced fulminant hepatic failure indirectly; via increasing hepatocyte survival and minimizing apoptosis. Such effects resulted from the secretion of large fractions of chemotactic cytokines or chemokines by MSCs (Wang et al., 2017). These findings are in consistence with those of Christ et al. (2015) who stated that MSCs, harbor pro-proliferative, immunomodulatory, anti-inflammatory and anti-apoptotic properties; which are desirable in liver diseases treatment. MSCs could release paracrine factors needed for functional liver restoration and both chronic and acute liver diseases treatment. Indeed, their pleiotropic actions include cell proliferation stimulation, immune reactions modulation and cell death responses attenuation; which are responsible for MSCs hepatocyte differentiation capacity.

In conclusion

Taken together, these studies indicated that MSCs therapy of diabetic metabolic abnormalities in addition to markedly hepato-renal dysfunction was superior to insulin treatment; which might have glycemic and metabolic control but was less effectively improve diabetic complications. BM-MSCs beneficial effects may involve individual or combinatorial effects of various protective processes, e.g., cells differentiation and regeneration, anti-inflammatory potency, immune modulation and protection capacity and control of hyperglycemia; however, the complete derivation of the exact mechanisms of action have yet to be elucidated.

References:-

1. Abdel-Razek, H.A.D. (2010): Beneficial effect of L-Carnitine on the neuromuscular performance in diabetic rats. Menoufyia Medical Journal, 23 (2) : 159-174.

2. Adam, S.H.; Giribabu, N.; Kassim, N.; Kumar, K; Brahmayya, M. and Salleh, N. (2016): Protective effect of aqueous seed extract of VitisVinifera against oxidative stress, inflammation and apoptosis in the pancreas of adult male rats with diabetes mellitus. Biomedicine and Pharmacotherapy, 81 : 439-452.

3. Alsairafi, Z.K; Smith, F.J.; Taylor, K.M.J.; Alsaleh, F. and Alattar, A.T. (2018): A qualitative study exploring patients’ experiences regarding insulin pump use. Saudi Pharmaceutical Journal, https://doi.org/10.1016/j.jsps.2018.02.010.
4. Amer, M.G.; Embaby, A.S.; Karam, R.A. and Amer, M.A. (2018): Role of adipose tissue derived stem cells differentiated into insulin producing cells in the treatment of type I diabetes mellitus. Gene, 654 : 87-94.

5. Antony, P.J.; Gandhi, G.R.; Stalin, A.; Balakrishna, K. and Al-Dhabi, N.A. (2017): Myoinositol ameliorates high-fat diet and streptozotocin-induced diabetes in rats through promoting insulin receptor signaling. Biomedicine and Pharmacotherapy, 88 : 1098-1113.

6. Arcaro, C.A.; Gutierrez, V.O.; Assis, R.P.; Moreira, T.F.; Costa, P.J.; Baviera, A.M. and Brunetti, L.L. (2014): Pinepherine, a Natural Bioenhancer, Nullifies the Antidiabetic and Antioxidant Activities of Curcumin in Streptozotocin-Diabetic Rats. PLOS ONE, 1-27.

7. Arya, A.; Cheaha, S.C.; Looia, C.Y.; Tahaa, H. and Mohda, M.A. (2012): The methanolic fraction of Centratherum anthelminticum seed downregulates pro-inflammatory cytokines, oxidative stress, and hyperglycemia in STZ-nicotinamide-induced type 2 diabetic rats. Food and Chem. Toxicol. J., 50 (11) : 4209-4220.

8. Bhansali, A.; Asokumar, P.; Walia, R.; Bhansali, S.; Gupta, V. and Jain, A. (2014): Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type II diabetes mellitus: a randomized placebo controlled study. Cell Transplant., 23 (9) : 1075-1085.

9. Cariou, B.; Leiter, L.A.; Mu¨ller-Wieland, D. Colhoun,D.M.; and Bujas-Bobanovic, M. (2017): Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM trial. Diabetes and Metabolism 43 : 453-459.

10. Chen, C.; Cohrs, C.M.; Stertmann, J. and Speie, S. (2017): Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis. MOLECULAR METABOLISM, 6 : 943-957.

11. Chen, Z. (2016): Adapter proteins regulate insulin resistance and lipid metabolism in obesity. Science Bulletin, 61 (19) : 1489-1497.

12. Chien, H.; Lee, T.; Chen, C.; Chiu, Y.; Lin, Y.; Lee, L. and Li, W. (2015): Circulating microRNA as a diagnostic marker in populations with type II diabetes mellitus and diabetic complications. Chinese Med. Association J., 78 (4) : 204-211.

13. Christ, B.; Brückner, S. and Winkle, S. (2015): The Therapeutic Promise of MSC for Liver Restoration. Trends in Molecular Biology, 21 (11) : 673-686.

14. Davey, G.C.; Patil, S.P.; O'Loughlin A. and O'Brien, T.(2014): Mesenchymal stem cell-based treatment for microvascular and secondary complications of Diabetes mellitus. Frontiers in Endocrinology, 5 (86) : 1-16.

15. Davies, L.C.; Alm, J.J.; Heldring, N.; Moll, G.; Gavin, C.; Batsis, I.; Qian, H. and Blanc, L. (2016): Type 1 Diabetes Mellitus Donor Mesenchymal Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro. STEM CELLS TRANSLATIONAL MEDICINE, 5 : 1485-1495.

16. Dewar, L. and Heuberger, R. (2017): The effect of acute caffeine intake on insulin sensitivity and glycemic control in people with diabetes. Diabetes and Metabolic Syndrome:https://doi.org/10.1016/j.dsxs.2017.04.017.

17. El Barky, A.R.; Ezz, A.A. and Elmean-Eldeen, A.A. (2018): Can Stem Cells Ameliorate the Pancreatic Damage Induced by Streptozotocin in Rats? Canadian Journal of Diabetes, 42 (1) : 61-70.

18. El-Kholy, W.M.; El-Habib, E.M. and El-Sawah, S.G. (2011): The ameliorating effect of Aloe vera gel extract on the altered metabolic and antioxidant status in streptozotocin-diabetic rats. Egypt. Ger. Soc. Zool. J., 63A: Comparative physiology : 133-154.

19. Elmarakby, A.; Faulkner, J.; Saleh, M.A. and Sullivan, J.C. (2012): Induction of hemeoxygenase-1 reduces glomerular injury and apoptosis in diabetic spontaneously hypertensive rats. Am J Physiol Renal Physiol., 302 : 791-800.

20. El-Sharaky, A.S.; Newairy, A.A.; Badr-Eldeen, M.M.; Eweda, S.M. and Sheweita, S.A. (2007): Protective role of selenium against renal toxicity induced by cadmium in rats. Toxic. J., 235 : 185-193.

21. Ène, A.; Nwankwo, E. and Sandi, L. (2007): Alloxaan-induced diabetes in rats and the effects of black caraway (Carum carvi l.) oil on their body weight. Res. J. Medic. Med. sciences, 2 (2) : 48 – 52.

22. Fung, Y.; Tian, X.; Bai, S.; Hou, W. and Tong, H. (2012): Autologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin- induce diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines and the p38MAPK signaling pathway. Int J Mol Med., 30 : 85-92.

23. Fathi-Kazerooni, M.; Tavoosidana, G.; Khanjani, S.; Eslatkhah, H. and Kazemnejad, S. (2017): Comparative restoration of acute liver failure by menstrual blood stem cells compared with bone narrow stem cells in mice model. Cytotherapy, 19 (12) : 1474-1490.

24. Feig, D.I.; Kang, D. and Johnson, R.J. (2008): Uric acid and cardiovascular risk. N Engl J Med., 359 : 1811-1821.
25. Gao, D.; Xie, J.; Zhang, J.; Feng, C.; Yao, B.; Ma, K.; Li, J.; Wu, X.; Huang, S. and Fu, X. (2014): MSC attenuate diabetes-induced functional impairment in adipocytes via secretion of insulin-like growth factor-1. Biochemical and Biophysical Research Communications, 452 (1) : 99-105.

26. Ghosh, S.; Bhattacharyya, S.; Rashid, K. and C. Sil, P. (2015): Curcumin protects rat liver from streptozotocin-induced diabetic pathophysiology by counteracting reactive oxygen species and inhibiting the activation of p53 and MAPKs mediated stress response pathways. Tox Rep J., 2 : 365-376.

27. Giralt, A.; Denechaud, P.; Lopez-Mejia, LC.; Bonner, C.; Pattou, F.; Annicotte, J. and Fajas, L. (2018): E2F1 promotes hepatic gluconeogenesis and contributes to hyperglycemia during diabetes. Molecular Metabolism. doi: 10.1016/j.molmet.2018.02.011.

28. Gougeon, R. (2013): Insulin Resistance of Protein Metabolism in Type 2 Diabetes and Impact on Dietary Needs: A Review. Canadian Journal of Diabetes, 37 (2) : 115-120.

29. Hamza, A.H.; Al-Bishri, W.M.; Damiani, L.A. and Ahmed, H.H. (2016): Mesenchymal stem cells: a future experimental exploration for recession of diabetic nephropathy. RENAL FAILURE, 39 (1) : 67-76.

30. Hebert, S.L. and Nair, K.S. (2010): Protein and energy metabolism in type 1 diabetes. Clinical Nutrition, 29 (1) : 13-17.

31. Herman, M.E.; O’Keefe, J.H.; Bell, D.S.H. and Schwartz, S.S. and (2017): Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. Progress in Cardiovascular Diseases, 60 (3) : 422-434.

32. Huynh, K.; Bernardo, B.C.; McMullen, J.R. and Ritchie, R.H. (2014): Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacology and Therapeutics, 142 : 375-415.

33. Jaen, M.L.; Vilà, L.; Elias, I.; Jimenez, V.; Rodó, J.; Haurigot, V. and Bosch, F. (2017): Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs. Molecular Therapy: Methods and Clinical Development, 6 : 1-7.

34. James, H.A.; O’Neill, B.T. and Nair, K.S. (2017): Insulin Regulation of Proteostasis and Clinical Implications. Cell Metabolism, 26 (2) : 310-323.

35. Jamshidi, M.; Ziamajidi, N.; Khodadadi, I.; Dehghan, A. and Kalantarian, G. (2018): The effect of insulin-loaded trimethylchitosan nanoparticles on rats with diabetes type I. Biomedicine and Pharmacotherapy, 97 : 729-735.

36. Jiang, Z.; Liu, Y.; Niu, X.; Yin, J.; Hu, B.; Guo, S.; Fan, Y.; Wang, Y. and Wang, N. (2016): Exosomes secreted by human urine-derived stem cells could prevent kidney complications from type I diabetes in rats. Stem Cell Research and Therapy, 7 : 24-37.

37. Kalirai, S.; Stephenson, J.; Perez-Nieves, M.; Reeda, B. and Fisher, L. (2017): Primary care physician perspectives on basal insulin initiation and maintenance in patients with type 2 diabetes mellitus. Primary Care Diabetes, 648 : 1-8.

38. Katz, L.E.; Bacha, F.; Gidding, S. and Marcovina, S. (2018): Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes. The Journal of Pediatrics, In Press.

39. Koppe, L.; Nyam, E and Vivot, K. (2016): Urea impairs beta cell glycolysis and insulin secretion in chronic kidney disease. J Clin Invest., 126 : 3598-3612.

40. Koroglu, P.; Senturk, G.; Yucela, D.; Ozakpinar, O.B.; Urasc, F. and Arbaka, S. (2015): The effect of exogenous oxytocin on streptozotocin (STZ)-induced diabetic adult rat testes. Peptides j., 63 : 47-54.

41. Krijnen, P.A.J.; Simsek, S. and Niessen, H.W.M. (2009): Apoptosis in diabetes. Apoptosis, 14 : 1387-1388.

42. Kumar, A.; Pati, N. and Sarin, S. (2011): Use of Stem Cells for Liver Diseases: Current Scenario. Journal of Clinical and Experimental Hepatology, 1 (1) : 17-26.

43. Lee, C.; Chen, Y.F.; Wu, H.H. and Lee, O.K. (2018): Historical Perspectives and Advances in Mesenchymal Stem Cell Research for the Treatment of Liver Diseases. Gastroenterology, 154 (1) : 46-56.

44. Li, L.; Li, F.; Gao, F.; Yang, Y.; Liu, Y.; Guo, P. and Li, Y. (2016): Transplantation of mesenchymal stem cells improves type I diabetes mellitus. Cell and Tissue Research, 364 (2) : 345-355.

45. Li, W.; Cavelti-Weder, C.; Zhang, Y.; Clement, K.; Donovan, S.; Gonzalez, G.; Zhu, J.; Stemmann, M.; Zeng, S.; Meissner, A.; Weir, G. and Zhou, Q. (2014): Long-term persistence and development of induced pancreatic beta cells generated by lineage conversion of acinar cells. Nat Biotechnol, 32 : 1223-1230.

46. Li, X.; Li, H.; Luh, N.; Feng, Y.; Huang, Y. and Gao, Z. (2012): Iron increases liver injury through oxidative/nitrative stress in diabetic rats: Involvement of nitrotyrosination of glucokinase. Biochimie J., 94 (12) : 2620-2627.

47. Lin, D.; Qi, Y.; Huang, C.; Wu, M.; Wang, C.; Li, F.; Yang, C.; Yan, L. Ren, M and Sun, K. (2017): Associations of lipid parameters with insulin resistance and diabetes: A population-based study. Clinical Nutrition, In Press.
48. Lin, Y.Y.; Chen, C.Y.; Wu, S.C. and Din, S.T. (2013): Modulation of glucose and lipid metabolism by porcine adiponectin receptor 1-transgenic mesenchymal stromal cells in diet-induced obese mice. Cytotherapy, 15 (8) : 971-978.

49. Liu, X.; Zheng, P.; Wang, X.; Cheng, H. and Zhang, Z. (2014): A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type II diabetes. Cell Res Ther., 5 (2) : 57-66.

50. Lu, J.; Xia, Q. and Zhou, Q. (2017): How to make insulin-producing pancreatic β cells for diabetes treatment. Sci China Life Sci, 60 : 239-248.

51. Lv, S.S.; Liu, G.; Cheng, J. and Sun, A.L. (2013): MSCs transplantation ameliorates glomerular injury in streptozotocin-induced diabetic nephropathy in rats via inhibiting macrophage infiltration. Int Immunopharmacol., 17 : 275-282.

52. Manjusha; Aggarwala, N.; Nitesh and Guptac, P. (2012): Effect of petroleum ether extract of Sesbania sesban (Merr.) roots in streptozotocin (STZ) induced diabetes in mice. Asian Pacific J. of Tropical Biomed., 2 (3) : 1254–1260.

53. Mayyas, F.; Juradat, R. and Alzoubi, K.H. (2018): Cardiac effects of fish oil in a rat model of streptozotocin-induced diabetes. Nutrition, Metabolism and Cardiovascular Diseases, In Press.

54. Miyata, T. and Dan, T. (2012): Inhibition of advanced glycation end products (AGEs): An implicit goal in clinical medicine for the treatment of diabetic nephropathy? Diabetes Res Clin Pract., 82 (1) : 25-29.

55. Mohan, S. and Nandhakumar, L. (2014): Role of various flavonoids: Hypotheses on novel approach to treat diabetes. Med. Hypotheses and Ideas., 8 (1) : 1-6.

56. Monfrinia, M.; Donzelli, E.; Rodriguez-Menendez, V.; Oggoni, N. and Crippa, L. (2017): Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy Experimental Neurology, 288 : 75-84.

57. Murugananuth, U.; Srinivasan, S. and Vinothkumar, V. (2017): Antidiabetogenic efficiency of menthol, improves glucose homeostasis and attenuates pancreatic β-cell apoptosis in streptozotocin–nicotinamide induced experimental rats through ameliorating glucose metabolic enzymes. Biomedicine and Pharmacotherapy, 92 : 229-239.

58. Nagaishi, K.; Ataka, K.; Echizen, E. and Fujimiy, M. (2014): Mesenchymal stem cell therapy ameliorates diabetic hepatocyte damage in mice by inhibiting infiltration of bone marrow-derived cells. Hepatology, 59 (5) : 1816-1829.

59. Newairy, A.A.; Salama, A.F.; Hussien, H.M. and Yousef, M.L (2009): Propolis alleviates aluminium-induced lipod peroxidation and biochemical parameters in male rats. Food and Chem. Toxic. J., 47 : 1093-1098.

60. Nia, P.H.; Khorrarn, S.; Rezaazadeh, H; Safaiyan, A. and Tarighet-Esfanjani, A. (2018): The Effects of Natural Clinoptilolite and Nano-Sized Clinoptilolite Supplementation on Glucose Levels and Oxidative Stress in Rats with Type 1 Diabetes. Canadian Journal of Diabetes, 42 (1) : 31-35.

61. Ning, H.; Sun, Z.; Liu, Y.; Liu, L.; Hao, L.; Chu, Y.; Li, S. and Sun, C. (2016): Insulin Protects Hepatic Lipotoxicity by Regulating ER Stress through the PI3K/Akt/p53 Involved Pathway Independently of Autophagy Inhibition. Nutrients, 8 : 227-249.

62. Oche, O.; Soni, I.; Chilaka, N.G.; Samuel, N.U. and Samuel, A. (2014): Pancreatic islet regeneration and some liver biochemical parameters of leaf extracts of Vitex doniana in normal and streptozotocin-induced diabetic albino rats. Asian Pac. Trop. Biomed. J., 4(2) : 124–130.

63. Petit, J.M. (2017): Special features of diabetes associated with liver diseases. Médecine des Maladies Métaboliques, 11 (8) : 682-686.

64. Pitlounavici, E.; Fernandes, G.S. and Teixeira, L.C. (2013): Hemeoxygenase 1 improves glucose metabolism and kidney histological alteration in diabetic rats. DiabetolMetabSyndr., 5 : 3-16.

65. Qi, k.; Li, N. and Melino, G. (2017): Tissue regeneration: The crosstalk between mesenchymal stem cells and immune response. Cellular Immunol., In Press.

66. Ramanathan, R.; Rupert, S.; Selvaraj, S.; Satyanesan, J.; Vennila, R. and Rajagopa, S. (2017): Role of Human Wharton’s Jelly Derived Mesenchymal Stem Cells (WJ-MSCs) for Rescue of d-Galactosamine Induced Acute Liver Injury in Mice. Journal of Clinical and Experimental Hepatology,7 (3) : 205-214.

67. Ramesh, B.; Karuna, R.; Sreenivas, R.S.; Sasi, B.R.B. and Saralakumari, D. (2012): Effect of Comiphora mukul gum resin on hepatic marker enzymes, lipid peroxidation and antioxidants status in pancreas and heart of streptozotocin induced diabetic rats. Asian Pac J Trop Biomed., 2 (11) : 895-900.

68. Roche, E.; Enseñat-Waser, R.; Reig, J.A.; Jones, J. and León-Quinto, T. (2017): Therapeutic Potential of Stem Cells in Diabetes. Handbook of Experimental Pharmacology, 174 : 147-167.
69. Rookmaaker, M.B.; Verhaar, M.C. and De Boer H. (2007): Met-RANTES reduces endothelial progenitor cell homin to activated (glomerular) endothelium in vitro and in vivo. Am J Physiol Renal Hysiol., 293 : 624-630.

70. Si, Y.; Zhao, Y.; Hao, H.; Liu, J.; Guo, Y. and Mu, Y.(2017): Infusion of mesenchymal stem cells ameliorates hyperglycemia in type II diabetic rats: identification of a novel role in improving insulin sensitivity. Diabetes, 61 (6) : 1616-1625.

71. Singh, J. and Kakkar, P. (2013): Modulation of liver function, antioxidant responses, insulin resistance and glucose transport by Oxyxdilinicum stem bark in STZ induced diabetic rats. Food and Chem Tox J., 62 : 722-731.

72. Sirasanagandla, S.; BabuKasesti, R.B.; Girradur, S.R. and Chipada, A. (2013): Anti hyperglycemic and antihyperlipidemic activities of 2-(4-(2-hydroxybenzyl) amino]-phenyl amino-methyl]-phenol in STZ induced diabetic rats. Europ. Medicin. Chem. J., 66 : 400-406.

73. Sood, V.; Mittal, B.R.; Bansali, A.; Singh, B.; Khandelwal, N. and Marwaha, N. (2015): Biodistribution of 18F-FDG-labeled autologous bone marrow-derived stem cells in patients with type II diabetes mellitus: exploring targeted and intravenous routes of delivery. Clin Nucl Med., 40 (9) : 697-700.

74. Sordia, V.; Pellegrinina, S.; Kramperah, M.; Pantéh, G. and Piemonti, L. (2017): Stem cells to restore insulin production and cure diabetes. Nutrition Metabolism and Cardiovascular Diseases, doi.org/10.1016/j.numecd.2017.02.004.

75. Subramanian, S. and Hirsch, I.P. (2018): Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Endocrinology and Metabolism Clinics of North America. 47 (1) : 65-79.

76. Tabara, Y.; Arai, H.; Hirao, Y.; Takahashi, Y. and Matsud, F. (2017): Different inverse association of large high-density lipoprotein subclasses with exacerbation of insulin resistance and incidence of type 2 diabetes: The Nagahama study. Diabetes Research and Clinical Practice, 127 : 123-131.

77. Thakkar, U.G.; Vanikar, A. and Trivedi, H.L. (2017): Should we practice stem cell therapy for type 1 diabetes mellitus as precision medicine? Cytotherapy, 19 : 574-576.

78. Thakkar, U.G.; Trivedi, H.L. and Dave, S.D. (2016): Co-infusion of insulin-secreting adipose tissue-derived mesenchymal stem cells and hematopoietic stem cells: novel approach to management of type I diabetes mellitus. International Journal of Diabetes in Developing Countries, 36 (4) : 426-432.

79. Thomas, S.S.; Zhang, L. and Mitch, W.E. (2015): Molecular mechanisms of insulin resistance in chronic kidney disease. Kidney Int., 88 : 1233-1239.

80. Wang, S.; Li, Y.; Zhao, J.; Zhang, J. and Huang, Y. (2013): Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model. Biol Blood Marrow Transplant., 19 : 538-546.

81. Wang, Y.; Chen, X.; Cao, W. and Shi, Y. (2014): Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol., 15 (11) : 1009-1016.

82. Wang, Y.; Yan, J.; Zou, X.; Guo, K.; Zhao, Y.; Meng, C.; Yin, F. and Guo, L. (2017): Bone marrow mesenchymal stem cells repair cadmium-induced rat testis injury by inhibiting mitochondrial apoptosis. Chemico-Biological Interactions, 271 : 39-47.

83. Wang, Z.; Cao, J.; Li, D.; Zhang, X.; Liu, J.; Li, J.; Wang, M.; Liu, Y.; Xu, B. and Wang, H. (2015): Clinical efficacy of autologous stem cell transplantation for the treatment of type 1 diabetes mellitus: a meta-analysis. Cytotherapy, 17 (7) : 956-968.

84. Xie, M.; Chena, D.; Zhanga, F.; Willskyb, G.R.; Cransc, D.C and Ding, W. (2014): Effects of vanadium (III, IV)-chlorodipicolinate on glycolysis and antioxidant status in the liver of STZ-induced diabetic rats. Inorg. Biochem. J., 136 : 47-56.

85. Xie, Y.; Bowe, B.; Li, T.; Hong, X.; Yan, Y. and Al-Aly, Z. (2018): Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. Kidney International, 93 : 741-752.

86. Xu, J.; Ming, Q.; Wang, X.; Zhang, W.; Li, Z.; Wang, S.; Li, Y. and Li, L. (2017): Mesenchymal stem cells moderate immune response of type 1 diabetes. Cell and Tissue Research, 368 (2) : 239-248.

87. Yener, S.; Comlekci, A. and Akinci, B. (2008): Serum transforming growth factor-beta I levels in normoalbuminuric and normotensive patients with type 2 diabetes. Effect of metformin and rosiglitazone. Hormones, 7 : 70-76.

88. Zang, L.; Hao, H.; Liu, J.; Han W. and Mu, Y. (2017): Mesenchymal stem cell therapy in type II diabetes mellitus. Diabetology Metabolic Syndrome, 9 (36) : 1-11.

89. Zhang, C.; Wang, T.; Ma, J.; Liu, Y. and Wang, D. (2017): Protective effect of CDDO-ethyl amide against high-glucose-induced oxidative injury via the Nrf2/HO-1 pathway. The Spine Journal, 17 (7) : 1017-1025.

90. Zhou, J.; Zhang, Z. and Qian, G. (2016): Mesenchymal stem cells to treat diabetic neuropathy: A long and strenuous way from bench to the clinic. Cell Death Discovery, 2 : e16055; doi:10.1038/cddiscovery.
### Table 1: Serum glucose, insulin, C-peptide, HbA1c, AGEs and HO-1 levels.

|                      | Control                  | Diabetic (D)            | D + Insulin              | D + BM-MSCs             |
|----------------------|--------------------------|-------------------------|--------------------------|--------------------------|
| **Glucose (mg/100 ml)** | Mean ± SEM: 92.83 ± 4.64 | 395.20 ± 19.76<sup>a</sup> | 115.00 ± 5.75<sup>b</sup> | 108.30 ± 5.41<sup>b</sup> |
|                      | *                        | + 325.72               | + 23.88                  | + 16.66                  |
|                      | **                       | - 70.90                | - 72.59                  |                          |
|                      | ***                      |                        |                          | - 5.82                   |
| **Insulin (µ I U/ml)** | Mean ± SEM: 17.10 ± 0.86 | 9.22 ± 0.46<sup>a</sup> | 17.00 ± 0.85<sup>b</sup> | 16.97 ± 0.76<sup>b</sup> |
|                      | *                        | - 46.08                | - 0.58                   | - 0.76                   |
|                      | **                       | + 84.38                |                          | + 84.05                  |
|                      | ***                      |                        |                          | + 0.17                   |
| **C-peptide (ng/ml)** | Mean ± SEM: 0.85 ± 0.04  | 0.31 ± 0.02<sup>a</sup> | 0.37 ± 0.02<sup>a</sup> | 0.79 ± 0.04<sup>bc</sup> |
|                      | *                        | - 63.52                | - 56.47                  | - 7.05                   |
|                      | **                       | + 19.35                |                          | + 154.83                 |
|                      | ***                      |                        |                          | + 113.51                 |
| **HbA1c (%)**        | Mean ± SEM: 2.92 ± 0.15  | 4.94 ± 0.25<sup>a</sup> | 3.40 ± 0.17<sup>b</sup> | 3.10 ± 0.16<sup>b</sup> |
|                      | *                        | + 69.17                | + 16.43                  | + 6.16                   |
|                      | **                       | - 31.17                | - 37.24                  |                          |
|                      | ***                      |                        |                          | - 8.82                   |
| **AGEs (AU/mg protein)** | Mean ± SEM: 2.86 ± 0.14 | 8.58 ± 0.43<sup>a</sup> | 3.48 ± 0.19<sup>b</sup> | 3.24 ± 0.16<sup>b</sup> |
|                      | *                        | + 200                  | + 21.67                  | + 13.28                  |
|                      | **                       | - 59.44                | - 62.23                  |                          |
|                      | ***                      |                        |                          | - 6.89                   |
| **HO-1 (P mol/mg)**  | Mean ± SEM: 270.60 ± 13.53 | 72.00 ± 3.60<sup>a</sup> | 185.20 ± 9.26<sup>ab</sup> | 251.00 ± 12.55<sup>bc</sup> |
|                      | *                        | - 73.39                | - 31.55                  | - 7.24                   |
|                      | **                       | + 157.22               | + 248.61                 |                          |
|                      | ***                      |                        |                          | + 35.52                  |

Values expressed as mean ± SEM (n = 6). a, b and c are Significant differences (P ≤ 0.05) comparing to control, diabetic and diabetic insulin-treated groups respectively. *, ** and *** are % of change comparing to control, diabetic and diabetic insulin-treated groups respectively.

### Table 2: Serum TL, TG, TC, LDL-C and HDL-C levels.

|                      | Control                  | Diabetic (D)            | D + Insulin              | D + BM-MSCs             |
|----------------------|--------------------------|-------------------------|--------------------------|--------------------------|
| **Serum TL (mg/dl)** | Mean ± SE: 258.20 ± 12.91 | 544.00 ± 27.20<sup>a</sup> | 316.80 ± 15.99<sup>b</sup> | 278.75 ± 13.94<sup>b</sup> |
|                      | *                        | +110.68                 | + 22.69                  | + 7.95                   |
|                      | **                       | - 41.76                 | - 48.75                  |                          |
### Table 3: Serum total proteins, albumin and globulins levels.

| Serum TG (mg/dl) | Mean ± SEM | Control | Diabetic (D) | D + Insulin | D + BM-MSCs |
|------------------|------------|---------|--------------|-------------|-------------|
| Mean             | 59.16 ± 2.90 | 120.00 ± 6.00<sup>a</sup> | 84.60 ± 4.23<sup>ab</sup> | -12.01 ± 3.50<sup>b</sup> |            |
| **               |            | + 102.83 ± 4.30 | + 43.00 ± 18.32 |            |            |
| ***              |            | - 29.50 ± 41.66 | - 41.66 ± 43.00 |            |            |
| Serum TC (mg/dl) | Mean ± SEM | Control | Diabetic (D) | D + Insulin | D + BM-MSCs |
| Mean             | 78.00 ± 3.89 | 150.20 ± 7.51<sup>a</sup> | 101.00 ± 5.15<sup>ab</sup> | 88.25 ± 4.41<sup>b</sup> |            |
| **               |            | + 92.56 ± 29.48 | + 29.48 ± 102.83 |            |            |
| ***              |            | - 32.75 ± 17.25 | - 17.25 ± 29.48 |            |            |
| LDL-C (mg/dl)    | Mean ± SEM | Control | Diabetic (D) | D + Insulin | D + BM-MSCs |
| Mean             | 107.66 ± 0.45 | 144.86 ± 0.44<sup>a</sup> | 119.68 ± 0.66<sup>b</sup> | 110.65 ± 1.01<sup>b</sup> |            |
| **               |            | + 34.55 ± 11.16 | + 11.16 ± 92.56 |            |            |
| ***              |            | - 17.38 ± 7.54 | - 23.62 ± 92.56 |            |            |
| HDL-C (mg/dl)    | Mean ± SEM | Control | Diabetic (D) | D + Insulin | D + BM-MSCs |
| Mean             | 41.50 ± 2.07 | 18.66 ± 0.96<sup>a</sup> | 35.60 ± 1.78<sup>b</sup> | 36.40 ± 1.82<sup>b</sup> |            |
| **               |            | - 55.03 ± 14.21 | - 14.21 ± 18.66 |            |            |
| ***              |            | + 90.78 ± 36.40 | + 23.62 ± 18.66 |            |            |

Values expressed as mean ± SEM (n = 6). <sup>a</sup>, <sup>b</sup> and <sup>c</sup> are Significant differences (P ≤ 0.05) comparing to control, diabetic and diabetic insulin-treated groups respectively. *<sup>a</sup>, **<sup>b</sup> and ***<sup>b</sup> are % of change comparing to control, diabetic and diabetic insulin-treated groups respectively.
Table 4: Serum creatinine, urea and uric acid levels in different animal groups.

|                      | Control       | Diabetic (D)  | D + Insulin | D + BM-MSCs |
|----------------------|---------------|---------------|-------------|-------------|
| Creatinine (mg/dl)   | 0.46 ± 0.02   | 1.43 ± 0.07   | 0.52 ± 0.03 | 0.49 ± 0.02 |
|                      | * + 201.86    | + 13.04       | + 6.52      |             |
|                      | **            | - 63.63       |             | - 65.73     |
|                      | ***           |               |             | - 5.76      |
| Urea (mg/dl)         | 20.60 ± 1.03  | 76.75 ± 3.84  | 40.00 ± 2.00| 25.75 ± 1.29|
|                      | * + 272.57    | + 94.17       | + 25.00     |             |
|                      | **            | - 47.88       |             | - 66.44     |
|                      | ***           |               |             | - 35.62     |
| Uric acid (mg/dl)    | 1.46 ± 0.07   | 3.10 ± 1.16   | 2.15 ± 0.11 | 1.48 ± 0.07 |
|                      | * + 112.32    | + 47.26       | + 1.36      |             |
|                      | **            | - 30.64       |             | - 52.25     |
|                      | ***           |               |             | - 31.16     |

Values expressed as mean ± SEM (n = 6). a, b and c are Significant differences (P ≤ 0.05) comparing to control, diabetic and diabetic insulin-treated groups respectively. * and ** are % of change comparing to control, diabetic and diabetic insulin-treated groups respectively.

Table 5: Serum AST, ALT, ALP and γ-GT activities and total bilirubin level.

|                      | Control       | Diabetic (D)  | D + Insulin | D + BM-MSCs |
|----------------------|---------------|---------------|-------------|-------------|
| AST (u/l)            | 58.80 ± 2.94  | 113.60 ± 5.68 | 75.00 ± 3.75| 70.67 ± 3.53|
|                      | * + 93.19     | + 27.55       | + 20.18     |             |
|                      | **            | - 33.97       |             | - 37.79     |
|                      | ***           |               |             | - 5.77      |
| ALT (u/l)            | 32.00 ± 1.60  | 67.80 ± 3.39  | 52.00 ± 2.60| 35.50 ± 1.78|
|                      | * + 111.87    | + 62.50       | + 10.93     |             |
|                      | **            | - 23.30       |             | - 47.64     |
|                      | ***           |               |             | - 31.73     |
| ALP (u/l)            | 232.60 ± 111.63| 401.00 ± 20.05| 287.60 ± 14.38| 259.40 ± 12.97|
|                      | * + 72.39     | + 23.64       | + 11.52     |             |
|                      | **            | - 28.27       |             | - 35.31     |
|                      | ***           |               |             | - 9.80      |
| γ-GT (u/l)           | 32.00 ± 1.60  | 80.60 ± 4.03  | 44.20 ± 2.21| 37.20 ± 1.86|
|                      | * + 151.87    | + 38.12       | + 16.25     |             |
|                      | **            | - 45.16       |             | - 53.84     |
|                      | ***           |               |             | - 15.83     |
| Bilirubin (mg/dl) | Mean ± SEM | 0.59 ±0.03  | 2.09 ±0.04 a | 0.73 ±0.04 ab | 0.64 ±0.03 b |
|------------------|------------|-------------|-------------|-------------|-------------|
|                  | *          | + 254.23    | + 23.72     | + 8.47      |
|                  | **         |             | - 65.07     | - 69.37     |
|                  | ***        |             |             | - 12.32     |

Values expressed as mean ± SEM (n = 6). a, b and c are Significant differences (P ≤ 0.05) comparing to control, diabetic and diabetic insulin-treated groups respectively. *, ** and *** are % of change comparing to control, diabetic and diabetic insulin-treated groups respectively.